scholarly journals Case report: rare case of infiltration of small lymphocytic B-cell lymphoma in the thyroid gland of female patient with B-cell chronic lymphocytic leukemia (CLL-B/SLL-B)

2013 ◽  
Vol 6 (1) ◽  
pp. 1 ◽  
Author(s):  
Elżbieta Andrysiak-Mamos ◽  
Rafał Becht ◽  
Elżbieta Sowińska-Przepiera ◽  
Jakub Pobłocki ◽  
Justyna Syrenicz ◽  
...  
2012 ◽  
Vol 74 (5) ◽  
pp. 677-680 ◽  
Author(s):  
Takumi OKAWA ◽  
Hiroko HIRAOKA ◽  
Yuko WADA ◽  
Kenji BABA ◽  
Kazuhito ITAMOTO ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Eleftheria Hatzimichael ◽  
Konstantina Papathanasiou ◽  
Ioannis Zerdes ◽  
Stefanos Flindris ◽  
Alexandra Papoudou-Bai ◽  
...  

Background. Plasmablastic lymphoma (PBL) is a rare, aggressive B-cell lymphoma with poor prognosis usually found in the oral cavity of HIV-positive patients. Chronic lymphocytic leukemia (CLL) is an indolent B-cell lymphoma with a variable clinical course. Transformation of CLL to PBL as Richter’s syndrome is rare while coexistence of CLL and PBL at diagnosis is even rarer.Case Report. We describe a case of a male immunocompetent patient with an ileum-cecum valve mass and a soft tissue mass at the left humerus with histologic evidence of PBL with coexistence of CLL in the bone marrow and peripheral blood. Amputation of the patient’s left arm was inevitable, and the patient was started on bortezomib and dexamethasone. However, prolonged hospitalization was complicated by aspiration pneumonia, and the patient passed away.Conclusions. No standard of care exists for patients with PBL, and prognosis remains dismal. Concomitant presentation of hematological malignancies becomes increasingly recognized, and further insight is needed in order to delineate whether they originate from the same clone or from different ones.


2019 ◽  
Vol 9 (1) ◽  
pp. 59-61
Author(s):  
Bala Koteswara Rao P ◽  
◽  
Jayshree C Awalekar ◽  
Ajinkye Nashte ◽  
Rahul Surve ◽  
...  

2016 ◽  
Vol 7 (6) ◽  
pp. 321-329 ◽  
Author(s):  
Valentín Ortíz-Maldonado ◽  
Pablo Mozas ◽  
Julio Delgado

B-cell lymphoma 2 (BCL2)-type proteins are key regulators of the intrinsic or mitochondrial pathway for apoptosis. Since escape from apoptosis is one the main ‘hallmarks of cancer’, BCL2 inhibitors have emerged as promising therapeutic agents for diverse lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). Multiple clinical trials have shown efficacy of these agents in patients with relapsed/refractory disease with a favorable toxicity profile. Moreover, some clinical trials indicate that combination with monoclonal antibodies and other novel agents may enhance their effect.


Sign in / Sign up

Export Citation Format

Share Document